Enanta Pharmaceuticals Inc. logo

Enanta Pharmaceuticals Inc. (ENTA)

Market Closed
12 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
11. 90
+0.39
+3.3884%
After Hours
$
13. 13
+1.23 +10.3361%
272.33M Market Cap
- P/E Ratio
- Div Yield
189,669 Volume
-5.15 Eps
$ 11.51
Previous Close
Add Transaction
Day Range
11.11 12.1
Year Range
6.43 17.15
Want to track ENTA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago.

Zacks | 1 year ago
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks | 1 year ago
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.33 per share a year ago.

Zacks | 1 year ago
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks | 1 year ago
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.

Zacks | 1 year ago
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?

Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks | 1 year ago